Criteria to qualify for study: Drug used in study:
  • At least two prior treatment regimens with progression while on Ibrutinib.

CLL46

A Phase 1/2 Multicenter study evaluating the safely and efficacy of KTE-C19 in adult subjects with relapsed/refractory Chronic Lymphocytic Lymphoma.